Searchable abstracts of presentations at key conferences in endocrinology

ea0039ep29 | Diabetes | BSPED2015

Factors influencing type 1 diabetes control in children – a detailed local analysis of an NPDA dataset

Fang Clarissa , Trewella Emily , Aminu Kingi , Spowart Karen , Bridges Nicola , Alexander Saji

Background: National paediatric diabetes audit (NPDA) provides comparative data for local paediatric diabetes units (PDUs) on key care processes and overall HbA1c. More detailed analysis on other variables affecting HbA1c is undertaken at a national level, but not at an individual PDU level.Objective: To determine the factors influencing glycaemic control (HbA1c levels) in young children and adolescents with Type 1 Diabetes Mellitus (T1DM).<p class="...

ea0039ep47 | Diabetes | BSPED2015

Characteristics of newly diagnosed children with type 1 diabetes – DKA vs Non- DKA presentation

El Munshid Sarrah , Alexander Saji , Spowart Karen , Logan Karen , Aminu Kingi , Bridges Nicola

Background: Diabetic ketoacidosis (DKA) is a common presentation of newly diagnosed type 1 diabetes (T1DM) in children but increases the disease burden at diagnosis. In UK, average frequency of DKA presentation is reported as 25% with an international variation of 16 to 67%. Data on frequency variations within the UK is limited.Aim: To compare the demographic and clinical characteristics of DKA vs non-DKA presentations in children <16 years at diagno...

ea0005p255 | Thyroid | BES2003

Preliminary evidence for genetic heterogeneity in the autoimmune polyendocrinopathy and enteropathy syndrome (IPEX)

Owen C , Jennings C , Imrie H , Lachaux A , Bridges N , Cheetham T , Pearce S

The immune dysregulation, polyendocrinopathy and enteropathy, X-linked syndrome (IPEX), is a rare and devastating condition of male infants. Immune mediated diabetes and enteropathy occur before 6 months of age and other manifestations include hypothyroidism, recurrent infections and eczema. In 2001, IPEX was mapped to Xp11, an orthologous region to that for the murine model of T cell dysregulation, scurfy, and mutations in the forkhead transcription factor gene, FOXP3,...

ea0045oc6.7 | Oral Communications 6- Endocrine | BSPED2016

Early treatment with rhGH in patients with Prader-Willi syndrome results in improved height with no respiratory adverse effects

Alatzoglou Kyriaki , Gopalakrishnamoorthy Mahalakshmi , Trewella Emily , Mulla Aayesha , Tan Hui-Leng , Bridges Nicola

Background: Prader-Willi syndrome (PWS) is a complex genetic disorder caused by lack of expression of paternally inherited imprinted genes on Chr15q11-q13. rhGH has beneficial effects on growth, body composition and development. Starting age, dose titration and monitoring remain controversial.Objective: To study retrospectively children who presented in our multidisciplinary PWS clinic and assess response to rhGH treatment in terms of auxology, IGF1 conc...

ea0024p19 | (1) | BSPED2010

Outcome of rhGH treatment in patients with achondroplasia and skeletal dysplasias

Alatzoglou K S , Mohan R , Ward S , Bridges N , Brook C G D , Hindmarsh P C , Dattani M T

Background and aim: Achondroplasia (ACH) is one of the commonest skeletal dysplasias affecting 1:15 000–1:40 000 live births. The average attained adult height is 131±5.6 cm for men and 124±5.9 cm for women. Previous studies have shown that the use of rhGH may result in transient increase in the growth rate, but there have been no long-term data regarding adult height. We aimed to study a cohort of patients with ACH and other skeletal dysplasias who have been tr...

ea0045p34 | Diabetes | BSPED2016

Continuous Subcutaneous Insulin Infusion results in better glycaemic control and reduced insulin requirements in CFRD: Report of 2 cases in children

Trewella E F , Spowart K , Nambisan A Kesavath Raman , Nolan SE , Carr S , Balfour-Lynn I M , Alexander Saji , Bridges Nicola

Introduction: Continuous Subcutaneous Insulin Infusion (CSII) has several advantages over Multiple Daily Injections (MDI) including better hourly delivery and avoidance of injections. However usage of CSII is significantly less in Cystic Fibrosis Related Diabetes (CFRD) compared to type 1 diabetes and published literature on use of CSII in children and adolescents with CFRD is minimal.We report two cases where CSII was used in CFRD resulting in a lower T...

ea0081p77 | Diabetes, Obesity, Metabolism and Nutrition | ECE2022

Comparison of hyperphagia and problem behaviors in participants with prader-willi syndrome (PWS) receiving diazoxide choline extended-release (DCCR) with matched participants in PATH for PWS (PfPWS)

Gevers Evelien , Strong Theresa , Miller Jennifer , Felner Eric , Goldstone Tony , Bridges Nicola , Yanovski Jack , Bird Lynne , Butler Merlin , Obrynba Kathryn , Lah Melissa , Shoemaker Ashley , Mejia-Corletto Jorge , Stevenson David , Wilding John , Kimonis Virginia , Abuzzahab Jennifer , Konczal Laura , Mathew Verghese , Cowen Neil , Woloschak Michael , Bhatnagar Anish

Background: PWS is a rare neurodevelopmental genetic disorder characterized by hyperphagia, obesity, hormonal deficiencies, and problem behaviors for which there are no approved treatment. DCCR administration (100-525 mg/day) up to 52 weeks in participants with PWS improved hyperphagia, behavior, body composition and metabolic markers.Objective: The objective of this study was to compare changes in hyperphagia (using Hyperphagia Questionnaire for Clinica...

ea0081ep360 | Diabetes, Obesity, Metabolism and Nutrition | ECE2022

Long-term safety of diazoxide choline extended-release (DCCR) tablets in patients with prader-willi syndrome

Gevers Evelien , Miller Jennifer , Butler Merlin , Bridges Nicola , Goldstone Tony , Obrynba Kathryn , Salehi Parisa , Felner Eric , Bird Lynne , Shoemaker Ashley , Konczal Laura , Lah Melissa , Yanovski Jack , Angulo Moris , Mejia-Corletto Jorge , Stevenson David , Wilding John , Abuzzahab Jennifer , Shaikh Guftar , Viskochil David , Mathew Verghese , Yen Kristen , Woloschak Michael , Bhatnagar Anish

Background: Prader-Willi syndrome (PWS), a rare genetic neurobehavioral-metabolic condition, is characterized by hyperphagia, accumulation of excess fat, hypotonia, and behavioral/psychological complications. There are no currently approved medications to treat hyperphagia in patients with PWS; DCCR is under development as a treatment for PWS.Objectives and Methods: The objective was to evaluate long-term safety of DCCR in individuals with PWS. 125 parti...

ea0005s51 | Alternative Careers for Endocrine Researchers | BES2003

Sales opportunities in biotech firms

Jackson S

With the changes in laboratory techniques affecting many disciplines, this is a short introduction to the variety of sales-based careers available in the UK biotechnology sector. The talk incorporates different companies, changing market trends and products and my own 'out of laboratory' experience of working in the biotech commercial world. Currently I work for Silicon Genetics, an American company with a small European operation based in the UK. I am their UK Regional Sales ...